Skip to main content
HR 3731 114th Congress House

RaD Fund Act

Official title: To establish a Rare Disease Therapeutics Corporation to encourage the development of high-risk, high-return therapies for rare diseases, and for other purposes.

Introduced: October 9, 2015 Introduced by: Vargas, Juan Democratic · California See on congress.gov
Health Advisory bodiesDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug therapy
More subjectsShow fewer subjects
Health programs administration and fundingHealth technology, devices, suppliesMedical researchNational Institutes of Health (NIH)Research administration and fundingResearch and development
Sign in to write a letter Sign in to watch
This bill died when the 114th Congress ended
It never became law before the 114th Congress (2015–2016) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 16, 2015
Referred to the Subcommittee on Health.
Oct 9, 2015
Introduced in House
Oct 9, 2015
Referred to the House Committee on Energy and Commerce.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action October 16, 2015

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Rare Disease Fund Act or the RaD Fund Act

This bill requires the National Institutes of Health (NIH) to organize the Rare Disease Therapeutics Corporation to purchase rights to, fund the development of, and sell ownership interests in drugs, biological products, and medical devices for rare diseases.

The NIH must sell stock in the corporation to investors as soon as practicable. The corporation and the NIH may enter into an agreement under which the NIH maintains an ownership interest in the corporation in exchange for providing the corporation with intellectual property or other assistance. The corporation is prohibited from paying dividends on its stock.

The corporation must sell its interest in a rare disease therapy prior to the therapy entering large-scale clinical trials.

The corporation must issue bonds guaranteed by the United States and may issue bonds backed by the corporation. For purposes of securities laws, the securities of the corporation are not issued or guaranteed by the federal government.

The bill establishes within the NIH the Rare Disease Therapeutics Corporation Science Advisory Council to advise the corporation on the purchase, sale, and development of rare disease therapies.
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 3731: RaD Fund Act. 114th Congress. Open America. https://openamerica.io/bill/114-HR-3731/
MLA
"H.R. 3731: RaD Fund Act." 114th Congress, 2026, Open America, https://openamerica.io/bill/114-HR-3731/.
Bluebook (legal)
H.R. 3731, 114th Cong. (2026), https://openamerica.io/bill/114-HR-3731/.
Markdown link
[H.R. 3731: RaD Fund Act](https://openamerica.io/bill/114-HR-3731/)
Report a problem